2014 Fiscal Year Final Research Report
Novel therapy for rheumatoid arthritis using T cell signaling agents.
| Project/Area Number |
24791002
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
MAEDA Shinji 名古屋市立大学, 医学(系)研究科(研究院), 助教 (80381854)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 関節リウマチ / 制御性Ｔ細胞 |
|---|
| Outline of Final Research Achievements |
Regulatory T cells (Tregs) play an important role in self-tolerance, whereas various inflammatory conditions, such as rheumatoid arthritis (RA), attenuate the suppressive function. The purpose of this study is to clarify the modulation of Tregs by agents affecting T cell signaling, providing a basis for novel therapeutic approach for immunological remission.
We have examined the change of phenotypes and the amount of circulating Tregs in human (RA) and mice (BALB/c, Collagen antibody induced arthritis,CAIA) in vivo. In mice, Tregs are increased by mTOR inhibitor (Everolimus) and IL-2CAc (IL-2 cytokine/mIL-2 antibody (JES6-1) complexes). Furthermore, maximum arthritis severity are significantly attenuated by IL-2CAc. In humans with RA, after 4wks CTLA-4-Ig (Abatacept) therapy, the ratio of resting Tregs in CD4 + T cells significantly increased, whereas activated Tregs decreased. Altering T cell signaling using various agents can control Tregs.
|
| Free Research Field |
リウマチ学
|
